Sion Glyn-Jones, Muhammad K Javaid, David Beard, Julia Newton, Robert Kerslake, Callum McBryde, Tim Board, Susan J Dutton, Melina Dritsaki, Vikas Khanduja, Magbor Akanni, Shaun Sexton, John Skinner, Nicholas Peckham, Ruth Knight, Ines Rombach, Loretta Davies, Vicki Barber
BACKGROUND: People with avascular necrosis of the hip have very limited treatment options currently available to stop the progression of this disease; this often results in the need for a hip replacement. There is some weak evidence that a class of drugs called bisphosphonates may delay the course of the disease, and this trial was commissioned and set up to provide robust evidence regarding the use of bisphosphonates in adults aged ≥ 18 years with this condition. OBJECTIVES: The aim of the Managing Avascular Necrosis Treatments: an Interventional Study ( MANTIS ) trial was to evaluate the clinical effectiveness and cost-effectiveness of a 12-month course of alendronate in the treatment of avascular necrosis...
October 2022: Health Technology Assessment: HTA